ATR

AptarGroup, Inc. 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for AptarGroup, Inc., a Delaware corporation, for the period ended September 30, 2003. The company operates in the packaging components industry, developing, manufacturing, and selling consumer product dispensing systems. It reports through two primary segments: Dispensing Systems (non-aerosol pumps, closures, valves) and SeaquistPerfect (aerosol valves and accessories). As of November 6, 2003, there were 36,293,545 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17% in Q3 and 21% for the nine months ended September 30, 2003, compared to the prior year. Approximately $19 million (Q3) and $70 million (9 months) of this increase was attributable to favorable foreign currency translation (weaker U.S. dollar vs. Euro).
• Margin Compression: Operating margins declined slightly (10.8% in Q3 2003 vs. 12.1% in Q3 2002). Cost of sales as a percentage of net sales increased to 66.0% (Q3) from 64.4% (prior year) due to higher tooling/equipment sales (lower margin), a strengthening Euro increasing European production costs, and start-up costs for new products.
• Unusual Items: The company recorded a $1.25 million charge for acquired research and development in Q3 2003 related to dry powder technology. This contrasts with a $4.2 million patent dispute settlement charge recorded in Q1 2002.
• Segment Performance: The Dispensing Systems segment saw EBIT grow 5% in Q3, while the SeaquistPerfect segment saw EBIT grow 54% in Q3, driven by productivity improvements and the elimination of low-margin accounts.

Guidance, Outlook, and Risks

• Outlook: Management expects strong sales in food/beverage and personal care markets to continue into Q4. However, they anticipate a modest reduction in fragrance/cosmetic orders and a planned inventory reduction by a major pharmaceutical customer, which will negatively impact Q4 pharmaceutical sales.
• Earnings Guidance: Diluted earnings per share for Q4 2003 are expected to be in the range of $0.45 to $0.50, compared to $0.50 in Q4 2002.
• Capital Expenditures: Full-year 2003 capital expenditures are estimated at $80 million to $85 million.
• Risks:
  • Currency: Significant exposure to the Euro; a strengthening Euro increases costs for European-produced goods sold in other currencies.
  • Competition: Increasing activity from Asian competitors may intensify price competition.
  • Liquidity: The company has a $100 million unsecured revolving credit agreement expiring June 30, 2004, with $73 million currently utilized. Management expects to renegotiate or extend this facility.
  • Tax: The company is in an overall foreign loss (OFL) tax situation in the U.S., meaning repatriating foreign dividends could incur tax costs (estimated at $2 million for the first $10 million repatriated).

Investor Verification Checklist

• Currency Impact: Verify the extent to which reported revenue growth is organic versus driven by the weaker U.S. dollar (approx. 20% of 9-month sales increase).
• Margin Trends: Monitor the impact of tooling sales and European production costs on future gross margins, as these factors compressed margins in 2003.
• Debt Maturity: Confirm the status of the $100 million revolving credit facility expiring in June 2004.
• Q4 Visibility: Assess the impact of the major pharmaceutical customer's inventory reduction on Q4 revenue and earnings.
• Acquisition Integration: Review the performance of the newly acquired dry powder technology assets expensed in Q3.